PMC9815494_01
Computed Tomography (CT) images for our patient over the course of treatment. (A) The results of abdominal enhanced CT scan for the patient following two cycles of trastuzumab/pertuzumab/capecitabine therapy after the patient underwent radical surgery on 20 June 2020. (B) The results of abdominal CT scan for the patient following six cycles of trastuzumab/pertuzumab/capecitabine therapy on 12 September 2020. (C) The results of abdominal CT scan for the patient following two cycles of pyrotinib/bevacizumab/capecitabine therapy on 27 October 2020. (D) The results of a PET-CT scan for the patient following six cycles of pyrotinib/bevacizumab/capecitabine therapy on 20 January 2021. (E) Positron Emission Tomography-CT (PET-CT) scan showed our patient's condition on 5 July 2022.
fonc-12-1024677-g001.jpg
PMC9815494_01_fonc-12-1024677-g001.jpg
f1
Figure 1A ). Following six cycles of adjuvant therapy with trastuzumab, plus pertuzumab and capecitabine, CT images of abdomen showed nodules on the right side of the pelvic cavity larger than previously identified, and observed multiple new nodules in omental and peritoneal reflection, which were considered to be metastases; and the hepatogastric ligament, the mesangial area, the ileocecal junction, and the pelvic nucleus contained multiple, slightly larger inguinal lymph nodes (on both sides,  Figure 1B ). Following three cycles of treatment, abdominal CT scan revealed decreased pelvic effusion, and small nodules in the original peritoneal reflection that were not obvious, as compared to the time of regimen change on January 21, 2021 ( Figure 1C ). After three additional cycles of treatment, the Positron Emission Tomography-CT (PET-CT) showed the right pelvic nodule once again regressed ( Figure 1D ). On July 5, 2022, abdominal CT scan revealed scattered small lymph nodes in the hepatogastric ligament, the mesangial area, the retroperitoneum, and the bilateral inguinal region, suggesting the disease has no progression ( Figure 1E ).
A summary of the patient's treatment regimen.
fonc-12-1024677-g002.jpg
PMC9815494_01_fonc-12-1024677-g002.jpg
f2
Until the time of publication, pyrotinib and bevacizumab have been administered as a maintenance therapy, the patient's lesions are still stable, and no recurrence or metastasis has occurred within 22 months.  Figure 2  provides a timeline that includes relevant patient care data and treatment regimen.